Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: alpelisib plus fulvestrant
Sponsor: Novartis Pharmaceuticals